Amylin Attacked By Carl Icahn Over Buyout Secrecy

Amylin Pharmaceuticals Inc. (NASDAQ:AMLN) was under attack today from Carl Icahn over the board of that company’s refusal to comment on rumors of a rejected takeover offer. Icahn, who holds an almost 9% stake in the company, was irate after an offer of $22 per share may or may not have been rejected by the company and the company would not confirm or deny the rumors. The $22 offer apparently came from Bristol Myers Squibb and shareholders were not informed of the offer by the board in any way. Information about the deal, or lack thereof, came from media reports that the board had rejected it. Icahn called move by the  the board of the company...